Golimumab: Difference between revisions
From IDWiki
Content deleted Content added
Created page with "* Humanized monoclonal antibody targeting TNF * Indications including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis Category:Monoclonal antibodies" |
No edit summary |
||
| Line 1: | Line 1: | ||
* Humanized monoclonal antibody targeting TNF |
* Humanized monoclonal antibody targeting TNF |
||
* Indications including [[rheumatoid arthritis]], [[psoriatic arthritis]], and [[ankylosing spondylitis]] |
* Indications including [[rheumatoid arthritis]], [[psoriatic arthritis]], and [[ankylosing spondylitis]] |
||
* Adverse effects include URTI, sinusitis, bronchitis, viral infections (including hepatitis B reactivation), superficial fungal infections, invasive fungal infections, tuberculosis |
|||
** Also elevated ALT, local injection site reactions, hypertension, dizziness, paresthesia, constipation |
|||
[[Category:Monoclonal antibodies]] |
[[Category:Monoclonal antibodies]] |
||
Latest revision as of 18:37, 29 September 2025
- Humanized monoclonal antibody targeting TNF
- Indications including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
- Adverse effects include URTI, sinusitis, bronchitis, viral infections (including hepatitis B reactivation), superficial fungal infections, invasive fungal infections, tuberculosis
- Also elevated ALT, local injection site reactions, hypertension, dizziness, paresthesia, constipation
